Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EBITDA: 2014-2024

Historic EBITDA for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$208.6 million.

  • Spyre Therapeutics' EBITDA fell 2.70% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.6 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$208.6 million for FY2024, which is 13.92% up from last year.
  • Latest data reveals that Spyre Therapeutics reported EBITDA of -$208.6 million as of FY2024, which was up 13.92% from -$242.3 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' EBITDA ranged from a high of -$65.6 million in FY2021 and a low of -$242.3 million during FY2023.
  • For the 3-year period, Spyre Therapeutics' EBITDA averaged around -$178.6 million, with its median value being -$208.6 million (2024).
  • As far as peak fluctuations go, Spyre Therapeutics' EBITDA grew by 19.43% in 2021, and later tumbled by 185.80% in 2023.
  • Spyre Therapeutics' EBITDA (Yearly) stood at -$81.5 million in 2020, then rose by 19.43% to -$65.6 million in 2021, then dropped by 29.14% to -$84.8 million in 2022, then crashed by 185.80% to -$242.3 million in 2023, then grew by 13.92% to -$208.6 million in 2024.